Advanced search
Start date
Betweenand

Multi interventional study exploring HIV-1 residual replication: a step towards HIV-1 eradication and sterilizing cure

Grant number:13/11323-5
Support Opportunities:Regular Research Grants
Start date: March 01, 2015
End date: February 28, 2018
Field of knowledge:Health Sciences - Medicine
Principal Investigator:Ricardo Sobhie Diaz
Grantee:Ricardo Sobhie Diaz
Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
City of the host institution:São Paulo
Associated researchers:Alberto José da Silva Duarte ; Ermelindo Della Libera Junior ; Luiz Mário Ramos Janini ; Maria Cecilia Araripe Sucupira ; Telma Miyuki Oshiro Sumida

Abstract

This is an interventional proof of concept pilot study to explore the residual HIV replication. Thirty patients under effective HAART for over 2 years will be randomized after recruitment to six different groups and followed by 48 weeks. Group 1. Five patients will receive no further intervention in this group (control group) Group 2. Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks. Group 3. Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks. Group 4. Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks. Group 5. Five patients will receive antiretroviral intensification with dolutegravir for 48 weeks, and dendritic cell vaccine.* Group 6. Five patients will receive antiretroviral intensification with dolutegravir for 48 weeks, dendritic cell vaccine, the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks.* *These groups will not receive maraviroc intensification due to its potential effect in decreasing the chemotactic activity of dendritic cells (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (8)
(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)
AMINI, RAZIEH; KARAMPOOR, SAJAD; ZAHEDNASAB, HAMID; KEYUANI, HOSSEIN; GHEIASIAN, MASOUD; JALILIAN, FARID AZIZI. Serum levels of matrix metalloproteinase-2,-9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity. Brazilian Journal of Infectious Diseases, v. 24, n. 2, p. 144-159, . (13/11323-5)
SADIA SAMER; MUHAMMAD SHOAIB ARIF; LEILA BERTONI GIRON; JEAN PAULO LOPES ZUKUROV; JAMES HUNTER; BRUNA TERESA SANTILLO; GISLENE NAMIYAMA; JULIANA GALINSKAS; SHIRLEY VASCONCELOS KOMNINAKIS; TELMA MIYUKI OSHIRO; et al. Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294. Brazilian Journal of Infectious Diseases, v. 24, n. 2, p. 150-159, . (13/11323-5)
DIAZ, RICARDO SOBHIE; SHYTAJ, IART LUCA; GIRON, LEILA B.; OBERMAIER, BENEDIKT; LIBERA, JR., ERMELINDO DELLA; GALINSKAS, JULIANA; DIAS, DANILO; HUNTER, JAMES; JANINI, MARIO; GOSUEN, GISELE; et al. Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, v. 54, n. 5, p. 592-600, . (13/11323-5)
SHYTAJ, IART LUCA; PROCOPIO, FRANCESCO ANDREA; TAREK, MOHAMMAD; CARLON-ANDRES, IRENE; TANG, HSIN-YAO; GOLDMAN, AARON R.; MUNSHI, MOHAMEDHUSEN; PAL, VIRENDER KUMAR; FORCATO, MATTIA; SREERAM, SHEETAL; et al. Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. EMBO MOLECULAR MEDICINE, v. 13, n. 8, . (13/11323-5, 19/17461-7)
NDHLOVU, LISHOMWA C.; GIRON, LEILA B.; GALINSKAS, JULIANA; PREMEAUX, THOMAS A.; PANG, ALINA P. S.; DIAS, DANILO; DE ALMEIDA BAPTISTA, MARCELLA VASSAO; SHYTAJ, IART LUCA; MARICATO, JULIANA T.; FERREIRA, PAULO R. A.; et al. Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV. Journal of Infectious Diseases, v. N/A, p. 11-pg., . (20/10396-2, 19/17461-7, 13/11323-5)
SAMER, SADIA; NAMIYAMA, GISLENE; OSHIRO, TELMA; ARIF, MUHAMMAD SHOAIB; DA SILVA, WANESSA CARDOSO; ARARIPE SUCUPIRA, MARIA CECILIA; JANINI, LUIZ MARIO; DIAZ, RICARDO SOBHIE. Evidence of Noncompetent HIV after Ex Vivo Purging Among ART-Suppressed Individuals. AIDS Research and Human Retroviruses, v. 33, n. 10, p. 993-994, . (13/11323-5)
DE ALMEIDA BAPTISTA, MARCELLA VASSAO; DA SILVA, LAIS TEODORO; SAMER, SADIA; OSHIRO, TELMA MIYUKI; SHYTAJ, IART LUCA; GIRON, LEILA B.; PENA, NATHALIA MANTOVANI; CRUZ, NICOLLY; GOSUEN, GISELE CRISTINA; ABRAO FERREIRA, PAULO ROBERTO; et al. mmunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical tria. AIDS RESEARCH AND THERAPY, v. 19, n. 1, . (19/17461-7, 13/11323-5)
SADRAEIAN, MOHAMMAD; DA CRUZ, EDGAR FERREIRA; BOYLE, ROSS W.; BAHOU, CALISE; CHUDASAMA, VIJAY; RAMOS JANINI, LUIZ MARIO; DIAZ, RICARDO SOBHIE; GUIMARAES, FRANCISCO E. G.. Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV. ACS OMEGA, v. 6, n. 25, p. 16524-16534, . (13/11323-5, 13/07276-1)